The partnership will advance antibody drug conjugates for hard-to-treat cancers. Credit: Pawel Giovanni Cancemi/Shutterstock.com.

Debiopharm and SunRock Biopharma have signed an exclusive option and licence agreement to advance the development of specifically targeted antibody drug conjugates (ADCs) for hard-to-treat cancers.

Under the agreement, Debiopharm will further develop SunRock’s antibodies by incorporating its linker technologies, Multilink and AbYlink, for creating the new ADCs.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

New ADCs are being developed to target tumour-specific antigens for fighting cancers with significant unmet needs, including the types of tumours that express HER2/HER3.

SunRock Biopharma CEO Laureano Simón said: “We are really enthusiastic about the powerful synergy of SunRock antibodies and bispecific antibodies with Debiopharm’s ADC platform and clinical development capabilities.”

Multilink, a new cleavable linker platform intended for multidrug attachment, is compatible with any conjugation technology to create ADCs with a high drug-to-antibody ratio (DAR).

See Also:

This technology enables multiple payloads loading on an antibody for improved therapeutic effect.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pharmaceutical or other speciality biotech companies can use this platform for generating clinical-stage ADCs.

AbYlink is a rapid antibody conjugation technology for diagnostic uses and ADC preparation. It is a site-selective method that provides defined and invariable conjugation sites without any impact on antigen-binding regions.

Using this technology, researchers can design ADCs with improved safety, efficacy and specificity to meet the unmet medical requirements of patients through ADC innovation.

Debiopharm CEO Bertrand Ducrey said: “Our partnership with SunRock could result in the creation of highly innovative antibody-drug conjugates with the potential to tackle cancer in a new way and ultimately improve the lives of cancer patients.”